No Data
Meikang Biotech: 2024 Annual Report
Meikang Biotech: 2024 Annual Report Summary
MedicalSystem Biotechnology's Subsidiary Receives Registration Certificate for Fully Automatic Biochemical Analyzer
Medicalsystem Biotechnology (300439.SZ) subsidiary has obtained a medical instruments registration certificate.
Medicalsystem Biotechnology (300439.SZ) announces that its wholly-owned subsidiary Ningbo Medicalsystem Shengde Biotechnology Co., Ltd. (abbreviated...
Medicalsystem Biotechnology (300439.SZ): plans to use 0.1 billion yuan of idle raised funds to temporarily supplement working capital.
On March 14, Glonghui reported that Medicalsystem Biotechnology (300439.SZ) announced the convening of the eleventh meeting of the fifth Board of Directors and the tenth meeting of the fifth Supervisory Board on March 14, 2025, to review and approve the proposal regarding the temporary use of part of the idle raised funds to supplement working capital. It was agreed that the company would use 0.1 billion yuan of idle raised funds to temporarily supplement working capital, provided that the funding requirements for the raised funds investment projects and the planned use of raised funds are normal. The usage period shall not exceed 12 months from the date of approval by the Board of Directors and will be returned to the special account for raised funds upon maturity.
MedicalSystem Biotech Wins Equity Dispute Case
Investors Don't See Light At End Of Medicalsystem Biotechnology Co., Ltd's (SZSE:300439) Tunnel
